CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

NCT04990557 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Respiratory Infection

Interventions

DRUG: PD-1 and ACE2 Knockout T Cells
DRUG: PD-1 and ACE2 Knockout T Cells
DRUG: PD-1 and ACE2 Knockout T Cells

Sponsor

Mahmoud Ramadan mohamed Elkazzaz